Your search for ‘Norton Rose Fulbright LLP’ returned 1,189 results

The Quebec Commission des relations du travail recently dismissed a claim of bad faith bargaining against an employer because the parties did not explicitly address the issue in question and its consequences in their discussions.

The Quebec Court of Appeal held that section 2(d) of the Canadian Charter of Rights and Freedoms does not guarantee the economic effects of collective bargaining.

In "Gagnon c C2C inc.", the Quebec Court of Appeal upheld the firing of the president of a Quebec-based mining company who refused to travel to Ecuador to resolve a situation with a local partner when requested to do so by the board of directors.

The plaintiff (Bolibruck) had approximately 36 years' service with the Niagara Health System (NHS) when she claimed that she had been constructively dismissed.

The Quebec Court of Appeal ruled on an employer’s right to recover employees’ premiums to the effective date of changes to a supplemental group life insurance plan.

The forestry company Moulton Contracting had obtained licences from British Columbia to harvest timber on tracts of land in the territory of the Fort Nelson First Nation, which is a signatory to Treaty 8, entered into in 1899.

The Federal Court of Appeal recently released a significant decision in Gitxaala Nation v Canada granting the CAPP leave to intervene in a consolidated proceeding concerning the Northern Gateway pipeline project.

Human rights impacts of business operations will attract scrutiny at home and abroad if not managed well.

The Canadian Extractive Sector Transparency Measures Act came into force on June 1, 2015. The purpose of this legislation is to implement Canada's international commitments to fight corruption in the extractive industries.

On January 16, 2014, the Resource Revenue Transparency Working Group released its final recommendations for the creation of mandatory transparency standards that would see mining companies publicly traded on Canadian stock exchanges publicly disclose payments to governments.

Hoffmann-La Roche Limited ("Roche") brought an application pursuant to section 6 of the Patented Medicines (Notice of Compliance) Regulations for an order prohibiting the Minister of Health from issuing a Notice of Compliance to Apotex Inc. ("Apotex") in respect of its valganciclovir hydrochloride tablets (the "Apotex Product") until the expiry of Canadian Patent No. 2,154,721 (the "‘721 Patent").

The Canadian Agency for Drugs and Technologies in Health (CADTH) is inviting stakeholder comments and feedback on the appropriate health technology assessment process (HTA) to be used in the context of the Common Drug Review (CDR) as it relates to biosimilars (known as "subsequent entry biologics" – SEBs - in Canada).

Amgen Canada Inc. and Amgen Inc. (collectively, Amgen) markets and sells filgrastim in Canada under the name NEUPOGEN® for use in the treatment of neutropenia.

Prothonotary Lafrenière issued an order pursuant to section 6(5)(b) of the PM(NOC) Regulations striking all allegations relating to one of three patents asserted by Bayer Inc. and Bayer Intellectual Property GmbH.

Businesses of all sizes are increasingly becoming aware of the strategic and commercial value of intellectual property (IP).

On January 29, 2015, the Ontario Court of Appeal released its judgment in Moore v. Getahun, a decision that provides important clarity regarding the preparation and use of expert reports in the context of civil actions.

In Western Larch Limited v Di Poce Management Limited1, the Court of Appeal for Ontario recently heard an appeal from a case in which partial summary judgment was granted in a commercial dispute involving the exercise of a shotgun clause.